SCHEMBL12508331

SCHEMBL12508331

Cc1ccc(-c2ccc(Cl)cc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.44
PTGS2 P35354 5/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
PTGS1 P23219 2/20 0.42
FASN P49327 1/20 0.42
PTGES2 Q9H7Z7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD11B1 P28845 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91817 0.96 PDE3B (0.43) GRM2PTGS2PDE3BPDE3APTGS1
SCHEMBL14206977 0.89 PTGES2 (0.46) PTGS2PDE3BPDE3APTGS1PTGES2
SCHEMBL2741569 0.88 APEX1 (0.41) GRM2PTGS2PDE3BPDE3APTGS1
SCHEMBL23638836 0.87 GRM2 (0.49) GRM2PTGS2FASNKDM4ELMNA
SCHEMBL7870739 0.86 PTGS2 (0.44) PTGS2PTGS1FASNKDM4EALDH1A1
SCHEMBL91941 0.85 PTGES2 (0.41) GRM2PTGS2PDE3BPDE3APTGES2
SCHEMBL20898100 0.83 NPC1 (0.49) GRM2PTGS2PDE3BPDE3AFASN
SCHEMBL31067155 0.83 NPC1 (0.49) GRM2PTGS2PDE3BPDE3AFASN
SCHEMBL4567630 0.83 PDE3B (0.50) PTGS2PDE3BPDE3APTGS1PTGES2
SCHEMBL10018702 0.83 PTGS2 (0.48) PTGS2PDE3BPDE3APTGS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-9616037-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2017-04-11 US disclosed
US-20160206578-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2016-07-21 US disclosed
US-9302984-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2016-04-05 US disclosed
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-09-24 US disclosed
US-9050329-B1 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2015-06-09 US disclosed
US-20150141472-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-05-21 US disclosed
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA GRM2 4198/4885PTGS2 1910/4885PDE3B 1116/4885
US-20150141472-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA GRM2 4216/4885PTGS2 1859/4885PDE3B 1095/4885
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA GRM2 4216/4885PTGS2 1859/4885PDE3B 1095/4885
US-20160206578-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA GRM2 4216/4885PTGS2 1859/4885PDE3B 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.